Drug
Azd9291 Dosing
Azd9291 Dosing: highest development phase Phase 1, developed by AstraZeneca. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| AZD9291 tablet dosing NCT02161770 | Phase 1 | Solid Tumours |
Latest
No recent events.
Follow Azd9291 Dosing on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.